Zurück
  • ePoster
  • P029

Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies

Termin

Datum:
Zeit:
Redezeit:
Diskussionszeit:
Ort / Stream:
Headache theatre

Poster

Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies

Session

Thema

  • New developments in prophylactic medications and acute medications
  • © Conventus Congressmanagement & Marketing GmbH